Duman, Ronald S
Aghajanian, George K
Sanacora, Gerard
Krystal, John H
Article History
Received: 11 March 2015
Accepted: 21 January 2016
First Online: 3 March 2016
Competing interests
: R.S.D. has served as a consultant for Pfizer, Eli Lilly and Company, Johnson and Johnson, Bristol-Myers Squibb, Lundbeck, Forest Laboratories, Taisho Pharmaceuticals, Sunovion Pharmaceuticals and Naurex. R.S.D. has also received research support from Eli Lilly and Company, Forest Laboratories, Taisho Pharmaceuticals, Sunovion Pharmaceuticals and Naurex. G.K.A. has no competing financial interests. G.S. has served as a consultant for Allergan, Alkermes, AstraZeneca, Avanier Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Hoffman La-Roche, Janssen, Merck and Company, Navigen, Naurex, Noven Pharmaceuticals, Servier Pharmaceuticals, Taisho Pharmaceuticals, Takeda, Teva and Vistagen Therapeutics. G.S. has also received additional research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Johnson and Johnson, Hoffman La-Roche, Merck and Company, Naurex and Servier over the last 24 months. Free medication was provided to G.S. for an NIH-sponsored study by Sanofi-Aventis. J.H.K. serves as a consultant for Amgen, AstraZeneca, Biogen, Biomedisyn, Forum Pharmaceuticals, Janssen Research and Development, Otsuka America, Sage Therapeutics, Sunovion and Takeda Industries. J.H.K. is on the scientific advisory board of Lohocla Research, Luc Therapeutics and Pfizer Pharmaceuticals and receives research support from Lohocla Research, Luc Therapeutics and Pfizer Pharmaceuticals. G.S. and J.H.K. hold shares in BioHaven Pharmaceuticals Holding Company and are co-inventors on a US patent (#8,778,979) held by Yale University.